Skip to main content
Premium Trial:

Request an Annual Quote

RXi Inks Deal to Sell Anti-scarring Drug in EU Prior to Approval

Premium

RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.

According to RXi, Ethicor will be able to supply the drug before it receives regulatory clearance under EU legislation that allows authorized health care professionals to administer such agents to individual special-needs patients under their care. The unapproved drug may not be marketed to doctors, however.

Under the terms of their deal, RXi and Ethicor will share the sales from RXI-109. Once the drug receives regulatory approval, RXi will regain the marketing rights to the drug.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.